Extended Data Fig. 4: hrIL6 regulates CaMKII post-translation modification in ECs.
a, Schematic diagram of the experimental setting: PECs were treated with the human recombinant IL-6 (hrIL6) at specific concentrations (0, 20, 50, 100 ng/ml) for 2 h. b, Immunoblots (Left) and quantitative plots (Right) demonstrate that hrIL6 dose-dependently increases CaMKII phosphorylation at Thr286 in PECs (n = 6). Error bars represent SD (b). Experiments were triplicated independently. P values were calculated using one-way ANOVA followed by Tukey’s post hoc test (b). Images created with BioRender.com (a). (***P < 0.001). Source data are provided as a Source Data file.
